Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Oncogene
    October 2024
  1. SAKAUE T, Dorayappan KDP, Zingarelli R, Khadraoui W, et al
    Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
    Oncogene. 2024 Oct 16. doi: 10.1038/s41388-024-03182.
    >> Share

  2. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    >> Share

  3. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    >> Share

  4. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    >> Share

  5. SUN X, Ye G, Li J, Yuan L, et al
    The tumor suppressor Parkin exerts anticancer effects through regulating mitochondrial GAPDH activity.
    Oncogene. 2024;43:3215-3226.
    >> Share

    September 2024
  6. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    >> Share

  7. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    >> Share

    August 2024
  8. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    >> Share

    June 2024
  9. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    >> Share

    May 2024
  10. PATTERSON MR, Meijers AS, Ryder EL, Wootton LM, et al
    E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
    Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067.
    >> Share

  11. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    >> Share

    April 2024
  12. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    >> Share

  13. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    >> Share

  14. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    >> Share

    February 2024
  15. MERIL S, Muhlbauer Avni M, Lior C, Bahlsen M, et al
    Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients.
    Oncogene. 2024 Feb 22. doi: 10.1038/s41388-024-02981.
    >> Share

    January 2024
  16. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    >> Share

  17. LIU H, Deng S, Yao X, Liu Y, et al
    Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
    Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
    >> Share

  18. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    >> Share

    December 2023
  19. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    >> Share

    November 2023
  20. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    >> Share

  21. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    >> Share

    October 2023
  22. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    >> Share

    September 2023
  23. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    >> Share

    August 2023
  24. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023 Aug 26. doi: 10.1038/s41388-023-02813.
    >> Share

  25. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    >> Share

    July 2023
  26. SCARTH JA, Wasson CW, Patterson MR, Evans D, et al
    Exploitation of ATP-sensitive potassium ion (K(ATP)) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK/AP-1 signalling.
    Oncogene. 2023 Jul 13. doi: 10.1038/s41388-023-02772.
    >> Share

  27. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    >> Share

    June 2023
  28. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    >> Share

    April 2023
  29. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    >> Share

    March 2023
  30. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    >> Share

  31. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    >> Share

    January 2023
  32. ZHANG C, Jiang H, Yuan L, Liao Y, et al
    CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
    Oncogene. 2023 Jan 19. doi: 10.1038/s41388-023-02595.
    >> Share

    December 2022
  33. LI G, Yi X, Du S, Gong L, et al
    Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition.
    Oncogene. 2022 Dec 8. doi: 10.1038/s41388-022-02560.
    >> Share

    November 2022
  34. WANG M, Yan Q, Song Y, Zhang Z, et al
    Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Oncogene. 2022 Nov 29. doi: 10.1038/s41388-022-02550.
    >> Share

  35. HE Y, OuYang Z, Liu W, Chen Y, et al
    TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing.
    Oncogene. 2022 Nov 11. pii: 10.1038/s41388-022-02539.
    >> Share

    October 2022
  36. HUANG TT, Burkett SS, Tandon M, Yamamoto TM, et al
    Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    Oncogene. 2022 Oct 12. pii: 10.1038/s41388-022-02491.
    >> Share

    August 2022
  37. DU QY, Huo FC, Du WQ, Sun XL, et al
    METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA.
    Oncogene. 2022 Aug 20. pii: 10.1038/s41388-022-02435.
    >> Share

    July 2022
  38. SHEN Z, Gu L, Liu Y, Wang L, et al
    PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA.
    Oncogene. 2022 Jul 22. pii: 10.1038/s41388-022-02411.
    >> Share

    June 2022
  39. HUANG C, Lv X, Chen P, Liu J, et al
    Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02390.
    >> Share

  40. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    Correction to: An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02356.
    >> Share

    May 2022
  41. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 May 30. pii: 10.1038/s41388-022-02354.
    >> Share

    April 2022
  42. ZHU S, Zhang C, Cao D, Bai J, et al
    Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02277.
    >> Share

  43. KOMATSU M, Nakamura K, Takeda T, Chiwaki F, et al
    Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.
    Oncogene. 2022;41:2326-2339.
    >> Share

    March 2022
  44. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 Mar 18. pii: 10.1038/s41388-022-02251.
    >> Share

    February 2022
  45. YOSHIDA A, Phillips-Mason P, Tarallo V, Avril S, et al
    Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
    Oncogene. 2022 Feb 24. pii: 10.1038/s41388-022-02243.
    >> Share

  46. KWON J, Choi H, Ware AD, Morillo BC, et al
    USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02224.
    >> Share

  47. LIAO Y, Huang J, Liu P, Zhang C, et al
    Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer.
    Oncogene. 2022 Feb 12. pii: 10.1038/s41388-022-02202.
    >> Share

  48. MOTA A, Oltra SS, Selenica P, Moiola CP, et al
    Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02221.
    >> Share

  49. LIN L, Shi K, Zhou S, Cai MC, et al
    SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02210.
    >> Share

    January 2022
  50. LI J, Zheng C, Wang M, Umano AD, et al
    ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02149.
    >> Share

  51. JAMES NE, Woodman M, Ribeiro JR
    Prognostic immunologic signatures in epithelial ovarian cancer.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-022-02181.
    >> Share

  52. KAN T, Zhang S, Zhou S, Zhang Y, et al
    Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02139.
    >> Share

    November 2021
  53. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    >> Share

  54. BOUDHRAA Z, Zaoui K, Fleury H, Cahuzac M, et al
    NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02082.
    >> Share

    May 2021
  55. KUMAGAI K, Takanashi M, Ohno SI, Harada Y, et al
    WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7.
    Oncogene. 2021;40:3695-3706.
    >> Share

    April 2021
  56. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021;40:2496-2508.
    >> Share

    March 2021
  57. NI M, Li J, Zhao H, Xu F, et al
    BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
    Oncogene. 2021 Mar 12. pii: 10.1038/s41388-021-01735.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016